临床试验
医学
中国
现状
药品
药物开发
靶向治疗
药理学
药品审批
业务
内科学
癌症
政治学
法学
作者
Huiyao Huang,Jingting Du,Xinyu Meng,Dawei Wu,Yue Yu,Shuhang Wang,Lili Wang,Wenya Wang,Yu Tang,Ning Li
标识
DOI：10.1016/j.jncc.2023.02.004
摘要
Research and development of targeted antitumor drugs in China are booming and advancing rapidly, and domestic enterprises have become the pillar. Encouraging genomics activities and establishing incentives and public-private collaboration frameworks are crucial for innovation-oriented drug development in China.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
OsamaKareem
学术文献互助
无极微光
MchemG
贪玩的秋柔
YifanWang
大力的灵雁
靤君
Hayat
缓慢怜菡
Rita
morena
loii
mmyhn
Criminology34
云飞扬
strike
8R60d8
AllRightReserved
皖公网安备34019202002308
